ACER Acer Therapeutics Inc

Price (delayed)

$2.88

Market cap

$41.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.68

Enterprise value

$25.31M

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer's pipeline includes four programs: ...

Highlights
ACER's EPS is up by 36% YoY and by 18% from the previous quarter
The company's net income rose by 26% YoY and by 15% QoQ
Acer Therapeutics's equity has increased by 27% from the previous quarter but it has decreased by 26% YoY
The company's quick ratio has shrunk by 81% YoY and by 19% QoQ

Key stats

What are the main financial stats of ACER
Market
Shares outstanding
14.31M
Market cap
$41.21M
Enterprise value
$25.31M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.96
Price to sales (P/S)
10.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.33
Earnings
Revenue
$4M
EBIT
-$19.43M
EBITDA
-$19.37M
Free cash flow
-$8.97M
Per share
EPS
-$1.68
Free cash flow per share
-$0.63
Book value per share
$0.73
Revenue per share
$0.28
TBVPS
$2.61
Balance sheet
Total assets
$44.51M
Total liabilities
$34.1M
Debt
$0
Equity
$10.41M
Working capital
$2.37M
Liquidity
Debt to equity
0
Current ratio
1.07
Quick ratio
0.76
Net debt/EBITDA
0.82
Margins
EBITDA margin
-484.4%
Gross margin
100%
Net margin
-486.5%
Operating margin
-484.1%
Efficiency
Return on assets
-87.1%
Return on equity
-192.8%
Return on invested capital
N/A
Return on capital employed
-185.5%
Return on sales
-486.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACER stock price

How has the Acer Therapeutics stock price performed over time
Intraday
-1.37%
1 week
-7.1%
1 month
5.88%
1 year
-8.57%
YTD
9.92%
QTD
-7.4%

Financial performance

How have Acer Therapeutics's revenue and profit performed over time
Revenue
$4M
Gross profit
$4M
Operating income
-$19.35M
Net income
-$19.45M
Gross margin
100%
Net margin
-486.5%
The company's operating income rose by 27% YoY and by 15% QoQ
The company's net income rose by 26% YoY and by 15% QoQ

Growth

What is Acer Therapeutics's growth rate over time

Valuation

What is Acer Therapeutics stock price valuation
P/E
N/A
P/B
3.96
P/S
10.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.33
ACER's EPS is up by 36% YoY and by 18% from the previous quarter
Acer Therapeutics's equity has increased by 27% from the previous quarter but it has decreased by 26% YoY
ACER's price to book (P/B) is 10% higher than its last 4 quarters average of 3.6 but 3.4% lower than its 5-year quarterly average of 4.1

Efficiency

How efficient is Acer Therapeutics business performance
Acer Therapeutics's ROE has plunged by 51% YoY but it has increased by 7% from the previous quarter
Acer Therapeutics's return on assets has increased by 42% QoQ and by 21% YoY

Dividends

What is ACER's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACER.

Financial health

How did Acer Therapeutics financials performed over time
Acer Therapeutics's total assets is 31% higher than its total liabilities
Acer Therapeutics's total assets has surged by 176% YoY
The company's quick ratio has shrunk by 81% YoY and by 19% QoQ
Acer Therapeutics's debt is 100% lower than its equity
Acer Therapeutics's equity has increased by 27% from the previous quarter but it has decreased by 26% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.